Keros Therapeutics Inc (KROS)

$17.39 +0.57 (3.39%)
Market Cap 513.66M
Revenue (ttm) 3.55M
Net Income (ttm) -187.35M
EPS (ttm) N/A
PE Ratio 10.95
Forward PE 8.78
Profit Margin -5,277.47%
Debt to Equity Ratio 0.00
Volume 1,439,400
Avg Vol 960,400
Day's Range N/A - N/A
Shares Out 30.47M
Stochastic %K 51%
Beta 1.12
Analysts Strong Sell
Price Target $23.25

Company Profile

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in pat...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 314 6297
Address:
1050 Waltham Street, Suite 302, Lexington, United States
Iightning
Iightning Nov. 22 at 1:01 AM
1ightning® Options Trade Alert (Actionable) | Buy $KROS Dec 19 $20 Call | Enter: $1.29 Exit: $2.33 | Profit: 80.62% ROI | https://1ightning.com
0 · Reply
Winning_calls
Winning_calls Nov. 21 at 5:49 PM
$KROS
0 · Reply
CyberCuba
CyberCuba Nov. 21 at 11:52 AM
$KROS $325 million cash now with 20 million shares outstanding after all greenmail and all tendered shares repurchased. Company says it has enough cash to fund operations through first six months of 2028
0 · Reply
Iightning
Iightning Nov. 21 at 4:23 AM
1ightning® Options Trade Alert (Actionable) | Buy $KROS Dec 19 $20 Call | Enter: $1.29 Exit: $2.33 | Profit: 80.62% ROI | https://1ightning.com
0 · Reply
CyberCuba
CyberCuba Nov. 20 at 1:10 PM
$KROS Exodus point capital management buys 1,907,899 shares of KROS per its November 18 SEC filing which will be just shy of 10% ownership of KROS once all the tendered shares are purchased by the company.
0 · Reply
Iightning
Iightning Nov. 20 at 1:58 AM
1ightning® Options Trade Alert (Actionable) | Buy $KROS Dec 19 $20 Call | Enter: $1.29 Exit: $2.33 | Profit: 80.62% ROI | https://1ightning.com
0 · Reply
Itinerant
Itinerant Nov. 19 at 3:34 PM
$KROS Tender offer is over subscribed. That is good, but the market takes it as bad.
0 · Reply
Iightning
Iightning Nov. 19 at 9:57 AM
1ightning® Options Trade Alert (Actionable) | Buy $KROS Dec 19 $20 Call | Enter: $1.29 Exit: $2.33 | Profit: 80.62% ROI | https://1ightning.com
0 · Reply
Puffyk
Puffyk Nov. 18 at 9:18 PM
$KROS when this explodes it is going to be MIGHTY. The accumulation and green candles consistently over the last month is impressive. It is ready to go incredibly high with a great update.
1 · Reply
CyberCuba
CyberCuba Nov. 18 at 4:36 PM
$KROS Will be interesting to see how well the $17.75 tender offer fared. If undersubscribed, there will be more cash left in the company. If oversubscribed, outstanding shares will now be closer to 20 million. Purchase of December $20 strike price call options has been brisk.
0 · Reply
Latest News on KROS
Keros Therapeutics Announces Final Results of Tender Offer

Nov 20, 2025, 4:01 PM EST - 1 day ago

Keros Therapeutics Announces Final Results of Tender Offer

Keros Therapeutics Announces Preliminary Results of Tender Offer

Nov 19, 2025, 6:00 AM EST - 3 days ago

Keros Therapeutics Announces Preliminary Results of Tender Offer

Keros Therapeutics Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:01 PM EST - 16 days ago

Keros Therapeutics Reports Third Quarter 2025 Financial Results

Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares

Oct 20, 2025, 6:00 AM EDT - 4 weeks ago

Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

Oct 15, 2025, 6:30 AM EDT - 5 weeks ago

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

Sep 8, 2025, 8:00 AM EDT - 2 months ago

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Aug 28, 2025, 4:01 PM EDT - 3 months ago

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

Aug 21, 2025, 8:30 AM EDT - 3 months ago

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

Aug 20, 2025, 9:48 AM EDT - 3 months ago

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Aug 6, 2025, 4:15 PM EDT - 3 months ago

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Keros Therapeutics Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:01 PM EDT - 3 months ago

Keros Therapeutics Reports Second Quarter 2025 Financial Results

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

Jul 17, 2025, 8:00 AM EDT - 4 months ago

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

Jun 9, 2025, 3:12 PM EDT - 5 months ago

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

Keros Announces Return of $375 Million in Excess Capital to Stockholders

Jun 9, 2025, 6:55 AM EDT - 5 months ago

Keros Announces Return of $375 Million in Excess Capital to Stockholders

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

Jun 6, 2025, 4:01 PM EDT - 6 months ago

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

May 29, 2025, 6:55 AM EDT - 6 months ago

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees

May 27, 2025, 1:45 PM EDT - 6 months ago

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees

ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

May 21, 2025, 8:00 AM EDT - 6 months ago

ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

May 12, 2025, 12:11 PM EDT - 6 months ago

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

May 12, 2025, 8:00 AM EDT - 6 months ago

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

Keros Reinforces Commitment to Maximizing Stockholder Value

May 8, 2025, 5:31 PM EDT - 7 months ago

Keros Reinforces Commitment to Maximizing Stockholder Value

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

May 8, 2025, 2:10 PM EDT - 7 months ago

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

May 6, 2025, 4:01 PM EDT - 7 months ago

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan

Apr 10, 2025, 1:51 PM EDT - 8 months ago

Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump

Apr 10, 2025, 12:12 PM EDT - 8 months ago

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump

Keros Therapeutics adopts 'poison pill' plan

Apr 10, 2025, 6:10 AM EDT - 8 months ago

Keros Therapeutics adopts 'poison pill' plan

Keros Therapeutics Announces Review of Strategic Alternatives

Apr 10, 2025, 6:00 AM EDT - 8 months ago

Keros Therapeutics Announces Review of Strategic Alternatives

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Mar 31, 2025, 6:00 AM EDT - 8 months ago

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:01 PM EST - 9 months ago

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

Feb 19, 2025, 10:41 AM EST - 9 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN LLY NVO REGN SRRK

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation

Jan 31, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 30, 2025, 10:00 AM EST - 10 months ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 8:00 AM EST - 10 months ago

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation

Jan 29, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Connect

Jan 28, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation

Jan 27, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation

Jan 26, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 24, 2025, 10:00 AM EST - 10 months ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect

Jan 23, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect

Iightning
Iightning Nov. 22 at 1:01 AM
1ightning® Options Trade Alert (Actionable) | Buy $KROS Dec 19 $20 Call | Enter: $1.29 Exit: $2.33 | Profit: 80.62% ROI | https://1ightning.com
0 · Reply
Winning_calls
Winning_calls Nov. 21 at 5:49 PM
$KROS
0 · Reply
CyberCuba
CyberCuba Nov. 21 at 11:52 AM
$KROS $325 million cash now with 20 million shares outstanding after all greenmail and all tendered shares repurchased. Company says it has enough cash to fund operations through first six months of 2028
0 · Reply
Iightning
Iightning Nov. 21 at 4:23 AM
1ightning® Options Trade Alert (Actionable) | Buy $KROS Dec 19 $20 Call | Enter: $1.29 Exit: $2.33 | Profit: 80.62% ROI | https://1ightning.com
0 · Reply
CyberCuba
CyberCuba Nov. 20 at 1:10 PM
$KROS Exodus point capital management buys 1,907,899 shares of KROS per its November 18 SEC filing which will be just shy of 10% ownership of KROS once all the tendered shares are purchased by the company.
0 · Reply
Iightning
Iightning Nov. 20 at 1:58 AM
1ightning® Options Trade Alert (Actionable) | Buy $KROS Dec 19 $20 Call | Enter: $1.29 Exit: $2.33 | Profit: 80.62% ROI | https://1ightning.com
0 · Reply
Itinerant
Itinerant Nov. 19 at 3:34 PM
$KROS Tender offer is over subscribed. That is good, but the market takes it as bad.
0 · Reply
Iightning
Iightning Nov. 19 at 9:57 AM
1ightning® Options Trade Alert (Actionable) | Buy $KROS Dec 19 $20 Call | Enter: $1.29 Exit: $2.33 | Profit: 80.62% ROI | https://1ightning.com
0 · Reply
Puffyk
Puffyk Nov. 18 at 9:18 PM
$KROS when this explodes it is going to be MIGHTY. The accumulation and green candles consistently over the last month is impressive. It is ready to go incredibly high with a great update.
1 · Reply
CyberCuba
CyberCuba Nov. 18 at 4:36 PM
$KROS Will be interesting to see how well the $17.75 tender offer fared. If undersubscribed, there will be more cash left in the company. If oversubscribed, outstanding shares will now be closer to 20 million. Purchase of December $20 strike price call options has been brisk.
0 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 4:31 PM
Oppenheimer has adjusted their stance on Keros Therapeutics ( $KROS ), setting the rating to Outperform with a target price of 23 → 27.
1 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 2:32 PM
Wells Fargo updates rating for Keros Therapeutics ( $KROS ) to Overweight, target set at 26 → 23.
1 · Reply
Swing_Tradr
Swing_Tradr Nov. 11 at 6:29 AM
Sneak peek at our Dashboard and TradrSense Pro's callout on $KROS with a price target of $21.20. The stock is in a strong uptrend, with the 50-day SMA above the 200-day SMA, signaling sustained upward momentum. Additionally, the price is above the 20-day SMA, indicating short-term strength. The RSI of 68.3 places it in the "healthy uptrend" zone, suggesting continued bullish momentum without being overbought.
0 · Reply
Winning_calls
Winning_calls Nov. 10 at 1:54 PM
$KROS 😉
0 · Reply
Winning_calls
Winning_calls Nov. 10 at 4:02 AM
$KROS pick me up @ $15.60
0 · Reply
MBSB
MBSB Nov. 6 at 8:34 PM
$KROS buying shares back at 17.75$…
1 · Reply
CyberCuba
CyberCuba Nov. 6 at 2:17 PM
$KROS Two quarters of "surprise" higher revenues and less losses per share. Maybe the median analyst consensus target price for KROS the next 12 months ($22.50) will be attained?
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 1:35 PM
Wedbush updates rating for Keros Therapeutics ( $KROS ) to Neutral, target set at 15 → 16.
0 · Reply
Puffyk
Puffyk Nov. 6 at 1:28 AM
$KROS BIIIIIIIIG RUN Coming Keros Therapeutics Q3 EPS $(0.18) Beats $(1.05) Estimate, Sales $14.262M Beat $3.800M Estimate Benzinga 2025-11-05T17:04:00-05:00 Keros Therapeutics (KROS.NaE) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(1.05) by 82.81 percent. This is a 87.23 percent increase over losses of $(1.41) per share from the same period last year. The company reported quarterly sales of $14.262 million which beat the analyst consensus estimate of $3.800 million by 275.32 percent. This is a 3.58K percent increase over sales of $388.000 thousand the same period last year.
0 · Reply
d_risk
d_risk Nov. 5 at 9:22 PM
$KROS - Keros Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors KROS’s latest 10-Q risk factors expand on funding needs, dilution risks, regulatory and clinical trial uncertainties (notably cibotercept’s TROPOS trial halt), animal testing disruptions, and post-approval compliance. IP litigation, licensing, and stockholder risks are detailed, with new disclosures on collaborations, cybersecurity, international ops, capital return, and anti-takeover measures. #Biotechnology #IntellectualProperty #FundingRisk #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/KROS/10-Q/2025-11-05
0 · Reply
CyberCuba
CyberCuba Nov. 4 at 3:30 PM
$KROS Open interest in December 17.50 call options keeps increasing. Outstanding shares will be about 20 million after tender offer completion November 18.
0 · Reply
buyandsold
buyandsold Oct. 31 at 2:36 PM
$SPRO i have been screwed so many times by management, most recently the $KROS greenmail. What could they do to us here? It seems rock solid, but I guess they could decide to burn money starting new trials on something completely new. Other ways this seemingly safe and solid stock may blow up?
4 · Reply